Stock Price Movement and Market Context
On 31 Dec 2025, Vivimed Labs’ stock price fell by 4.96% to ₹17.58, reaching its lowest level in the past 52 weeks. This decline comes after a sustained six-day losing streak, during which the stock has shed 26.36% of its value. The current price stands well below its 52-week high of ₹24.01, reflecting a notable contraction in market valuation.
Despite the broader market’s positive momentum, with the Sensex climbing 572.25 points (0.82%) to 85,365.83 and nearing its own 52-week high, Vivimed Labs has underperformed its sector by 5.71% on the day. The Sensex’s bullish trend is supported by its 50-day moving average trading above the 200-day moving average, while small-cap stocks led gains with a 1.06% rise. In contrast, Vivimed Labs’ stock price is trading below its 5-day moving average, though it remains above its 20-day, 50-day, 100-day, and 200-day moving averages, indicating short-term weakness amid longer-term support levels.
Financial Performance and Key Ratios
Vivimed Labs’ financial health has been under pressure, as reflected in its recent results and fundamental indicators. The company has not declared any financial results in the last six months, contributing to uncertainty around its current performance. The last reported half-yearly results showed a net loss (PAT) of ₹-281.57 crores, representing a decline of 34.93% compared to the previous period.
The company’s debt metrics remain a concern, with a debt-to-equity ratio of 9.60 times as of the last half-year, and a Debt to EBITDA ratio standing at a high 12.57 times. These figures indicate a significant leverage burden, which may constrain financial flexibility. Additionally, the debtors turnover ratio has fallen to 2.44 times, signalling slower collection efficiency and potential liquidity pressures.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Profitability and Return Metrics
The company’s profitability remains subdued, with an average Return on Equity (ROE) of just 1.75%, indicating limited returns generated on shareholders’ funds. Over the past year, Vivimed Labs’ profits have contracted sharply by 267.9%, underscoring the challenges faced in generating sustainable earnings.
In comparison, the Sensex has delivered a 9.27% return over the same period, highlighting the relative underperformance of Vivimed Labs. The company’s Mojo Score, a composite measure of financial health and market performance, stands at a low 24.0, with a Mojo Grade of Strong Sell as of 22 Dec 2025. This rating reflects weak long-term fundamentals and elevated risk factors.
Valuation and Risk Considerations
Vivimed Labs is currently trading at valuations that are considered risky relative to its historical averages. The absence of recent financial disclosures adds to the uncertainty surrounding the stock’s outlook. The company’s market capitalisation grade is rated 4, indicating a smaller market cap with associated liquidity and volatility considerations.
While the broader market environment remains positive, with indices trading near highs and small caps gaining traction, Vivimed Labs’ stock continues to face downward pressure. The stock’s recent performance and fundamental metrics suggest a cautious stance among market participants.
Vivimed Labs or something better? Our SwitchER feature analyzes this micro-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Recent Trends
Over the last six trading sessions, Vivimed Labs has experienced a consistent decline, losing over a quarter of its value. This trend contrasts sharply with the broader market’s upward trajectory, where indices and small-cap segments have shown strength. The stock’s moving averages indicate short-term weakness, with the price below the 5-day average but still supported by longer-term averages.
The company’s financial disclosures highlight significant losses and high leverage, factors that have contributed to the stock’s diminished appeal. The lack of recent results has further compounded uncertainty, reflected in the stock’s strong sell rating and low Mojo Score.
Investors monitoring the stock will note the divergence between Vivimed Labs’ performance and the broader market’s gains, underscoring the challenges faced by the company in regaining investor confidence and financial stability.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
